Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treat… Read more
Zealand Pharma A/S (ZLDPF) - Total Liabilities
Latest total liabilities as of September 2025: $1.63 Billion USD
Based on the latest financial reports, Zealand Pharma A/S (ZLDPF) has total liabilities worth $1.63 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zealand Pharma A/S - Total Liabilities Trend (2007–2024)
This chart illustrates how Zealand Pharma A/S's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zealand Pharma A/S Competitors by Total Liabilities
The table below lists competitors of Zealand Pharma A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BGC Group Inc.
NASDAQ:BGC
|
USA | $4.68 Billion |
|
Kyowa Kirin Co. Ltd
PINK:KYKOF
|
USA | $214.72 Billion |
|
Allreal Holding
SW:ALLN
|
Switzerland | CHF3.25 Billion |
|
The Siam Cement Public Company Limited
PINK:SCVPF
|
USA | $425.89 Billion |
|
Impulsora del Desarrollo y el Empleo en América Latina S.A.B. de C.V
MX:IDEALB-1
|
Mexico | MX$78.27 Billion |
|
NH Foods Ltd
F:NI6
|
Germany | €419.63 Billion |
|
Waystar Holding Corp. Common Stock
NASDAQ:WAY
|
USA | $1.52 Billion |
|
Enerjisa Enerji AS
IS:ENJSA
|
Turkey | TL114.06 Billion |
Liability Composition Analysis (2007–2024)
This chart breaks down Zealand Pharma A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zealand Pharma A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zealand Pharma A/S (2007–2024)
The table below shows the annual total liabilities of Zealand Pharma A/S from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $888.86 Million | +129.59% |
| 2023-12-31 | $387.15 Million | -46.52% |
| 2022-12-31 | $723.89 Million | -36.49% |
| 2021-12-31 | $1.14 Billion | +52.48% |
| 2020-12-31 | $747.52 Million | +109.48% |
| 2019-12-31 | $356.84 Million | +214.35% |
| 2018-12-31 | $113.52 Million | -45.63% |
| 2017-12-31 | $208.77 Million | -49.87% |
| 2016-12-31 | $416.43 Million | +8.88% |
| 2015-12-31 | $382.46 Million | +11.20% |
| 2014-12-31 | $343.93 Million | +1017.67% |
| 2013-12-31 | $30.77 Million | +2.68% |
| 2012-12-31 | $29.97 Million | +6.71% |
| 2011-12-31 | $28.08 Million | -35.35% |
| 2010-12-31 | $43.44 Million | +68.67% |
| 2009-12-31 | $25.75 Million | +55.06% |
| 2008-12-31 | $16.61 Million | -20.92% |
| 2007-12-31 | $21.00 Million | -- |